NCT00910598View on ClinicalTrials.gov

Optical Coherence Tomography: Glatiramer in Clinically Isolated Syndrome or Early Relapsing Remitting Multiple Sclerosis (MS)

PHASE4UnknownINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

September 30, 2009

Primary Completion Date

June 30, 2012

Study Completion Date

June 30, 2012

Conditions
Multiple Sclerosis
Interventions
DRUG

glatiramer acetate

20 mg daily s.c. for 1 year

Trial Locations (2)

4818 CK

RECRUITING

Amphia Ziekenhuis, Breda

Unknown

RECRUITING

Maasland Ziekenhuis, Sittard

Sponsors

Collaborators (1)

Sanofi
All Listed Sponsors
collaborator

Sanofi

INDUSTRY

collaborator

TEVA Pharmachemie

UNKNOWN

lead

Amphia Hospital

OTHER

NCT00910598 - Optical Coherence Tomography: Glatiramer in Clinically Isolated Syndrome or Early Relapsing Remitting Multiple Sclerosis (MS) | Biotech Hunter | Biotech Hunter